12:00 AM
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

BioMarin regulatory update

BioMarin said that EMA's CHMP recommended approval of an expansion to its biologics manufacturing facility in Novato, Calif. The company expects a final decision from EMA in 1Q12 on the expansion, which BioMarin expects to double the site's capabilities and support up to $1 billion in revenue for its enzyme replacement...

Read the full 235 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >